4722 related articles for article (PubMed ID: 6143562)
81. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
82. Mechanism of resistance to the oncolytic C-nucleoside 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC-286193).
Jayaram HN; Cooney DA; Glazer RI; Dion RL; Johns DG
Biochem Pharmacol; 1982 Aug; 31(15):2557-60. PubMed ID: 7126269
[No Abstract] [Full Text] [Related]
83. Isosteric analogues of nicotinamide adenine dinucleotide derived from furanfurin, thiophenfurin, and selenophenfurin as mammalian inosine monophosphate dehydrogenase (type I and II) inhibitors.
Franchetti P; Cappellacci L; Perlini P; Jayaram HN; Butler A; Schneider BP; Collart FR; Huberman E; Grifantini M
J Med Chem; 1998 May; 41(10):1702-7. PubMed ID: 9572896
[TBL] [Abstract][Full Text] [Related]
84. Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells.
Kharbanda SM; Miyazaki K; Takeyama H; Sherman ML; Spriggs DR; Carney WP; Kufe DW
Cancer Commun; 1989; 1(3):191-7. PubMed ID: 2639729
[TBL] [Abstract][Full Text] [Related]
85. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
Szekeres T; Fritzer M; Pillwein K; Felzmann T; Chiba P
Life Sci; 1992; 51(16):1309-15. PubMed ID: 1357518
[TBL] [Abstract][Full Text] [Related]
86. Advanced Lewis lung carcinoma cured by tiazofurin as a system to study delayed hemopoietic effects of cancer.
Balducci L; Hardy CL
Cancer Invest; 1988; 6(6):681-6. PubMed ID: 3245935
[TBL] [Abstract][Full Text] [Related]
87. Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.
Melink TJ; Sarosy G; Hanauske AR; Phillips JL; Bayne JH; Grever MR; Jayaram HN; Von Hoff DD
Sel Cancer Ther; 1990; 6(1):51-61. PubMed ID: 2343202
[TBL] [Abstract][Full Text] [Related]
88. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
89. Carboxamide group conformation in the nicotinamide and thiazole-4-carboxamide rings: implications for enzyme binding.
Li H; Goldstein BM
J Med Chem; 1992 Sep; 35(19):3560-7. PubMed ID: 1357174
[TBL] [Abstract][Full Text] [Related]
90. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
[TBL] [Abstract][Full Text] [Related]
91. Synergistic cytotoxic effect of tiazofurin and ribavirin in hepatoma cells.
Natsumeda Y; Yamada Y; Yamaji Y; Weber G
Biochem Biophys Res Commun; 1988 May; 153(1):321-7. PubMed ID: 2897852
[TBL] [Abstract][Full Text] [Related]
92. Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanism.
Hedstrom L; Wang CC
Biochemistry; 1990 Jan; 29(4):849-54. PubMed ID: 1971185
[TBL] [Abstract][Full Text] [Related]
93. Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Green RM; Stewart DJ; Maroun JA
Invest New Drugs; 1986; 4(4):387-94. PubMed ID: 3583646
[TBL] [Abstract][Full Text] [Related]
94. Cytotoxicity, differentiating activity and metabolism of tiazofurin in human neuroblastoma cells.
Pillwein K; Schuchter K; Ressmańn G; Gharehbaghi K; Knoflach A; Cermak B; Jayaram HN; Szalay SM; Szekeres T; Chiba P
Int J Cancer; 1993 Aug; 55(1):92-5. PubMed ID: 8344756
[TBL] [Abstract][Full Text] [Related]
95. Synthesis, conformational analysis, and biological activity of new analogues of thiazole-4-carboxamide adenine dinucleotide (TAD) as IMP dehydrogenase inhibitors.
Franchetti P; Cappellacci L; Pasqualini M; Petrelli R; Jayaprakasan V; Jayaram HN; Boyd DB; Jain MD; Grifantini M
Bioorg Med Chem; 2005 Mar; 13(6):2045-53. PubMed ID: 15727858
[TBL] [Abstract][Full Text] [Related]
96. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
[TBL] [Abstract][Full Text] [Related]
97. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase.
Sokoloski JA; Blair OC; Sartorelli AC
Cancer Res; 1986 May; 46(5):2314-9. PubMed ID: 2870796
[TBL] [Abstract][Full Text] [Related]
98. Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines.
Szekeres T; Schuchter K; Chiba P; Ressmann G; Lhotka C; Gharehbaghi K; Szalay SM; Pillwein K
Biochem Pharmacol; 1993 Dec; 46(11):1903-7. PubMed ID: 7903533
[TBL] [Abstract][Full Text] [Related]
99. Metabolism and action of benzamide riboside in Chinese hamster ovary cells.
Saunders PP; Arimilli S; Krohn K; Muhs MA; Alvarez E; Surve-lyer R
Anticancer Drugs; 1996 Jan; 7(1):93-9. PubMed ID: 8742104
[TBL] [Abstract][Full Text] [Related]
100. Tiazofurin induction of mouse erythroleukemia cell hemoglobin production in the absence of commitment or changes in protooncogene expression.
Sherman ML; Shafman TD; Colman MS; Kufe DW
Blood; 1989 Feb; 73(2):431-4. PubMed ID: 2917182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
